T-Bird Pharma Inc. V.TPI

this one is a real deal and no flackey promoters

[imcrazylikeafox]

i like supreme to

So there’s your full disclosure. And with that out of the way, the Undervalued Seven.

1. T-Bird Pharma (TSX:V.TPI, Stock Forum): This recent market launch came out at a decent $43m market cap (I predicted $35m), which many would have seen as a success, but I get the feeling the people behind the company were surprised they didn’t land alongside the Organigram’s and Tweed’s in the $100m range because, you know, they actually have their MMPR. There is a LOT of activity at T-Bird HQ right now, certainly more than you usually see post-IPO and, in fact, possibly more than was even going on before the launch. Volume is very low right now and the share structure is tight, all of which leaves me with the feeling this thing is going to get a lot of elbow shoved into it real soon which should push it beyond a buck and then some. Update: Between writing and posting this piece, has become a Stockhouse client.

2. Wildflower Marijuana (CSE:C.SUN, Stock Forum): There’s no more enthusiastic group in town than the dudes behind Wildflower. They’ve been very proactive in getting face time with me, and their story really does look interesting, but they took their time getting press after their mid-June launch, which has seen the share price linger at around $0.20. Only $30m shares out, only $5.7m market cap, and they’re deep into two MMPR applications in BC with word that another could be in the mix, and a significant tech component to their plan that, for mine, is a company builder. For details, watch this space: Deep dive soon. Stockhouse client.

3. Supreme Pharmaceuticals (CSE:C.SL, Stock Forum): Everything this company has done in the last few weeks has pointed to a big piece of news on the horizon, including yesterday’s release noting the security upgrades the company needs to complete its MMPR are near, and that the company will be ready for Health Canada prime time attention in November. New management is in, a capital markets advisor has been hired, the recent rollback has the share structure tight, and we keep hearing that their $5m raise to get grow-ready is a battleground for brokers looking to wedge their way in. Personally, I can’t even get them on the phone anymore, which tells me the carpets at Supreme HQ are dripping with sweat, drool and anticipation. With a $21.9m market cap, that MMPR should be a three-bagger when/if it comes.

Read more at https://www.stockhouse.com/news/newswire/2014/09/18/medical-marijuana-update-the-undervalued-seven#ochojtKpJkEHqowv.99